Single injections of apoA-I acutely improve in vivo glucose tolerance in insulin-resistant mice.

Summary, in English

Apolipoprotein A-I (apoA-I), the main protein constituent of HDL, has a central role in the reverse cholesterol-transport pathway, which together with the anti-inflammatory properties of apoA-I/HDL provide cardioprotection. Recent findings of direct stimulation of glucose uptake in muscle by apoA-I/HDL suggest that altered apoA-I and HDL functionality may be a contributing factor to the development of diabetes. We have studied the in vivo effects of short treatments with human apoA-I in a high-fat diet fed mouse model. In addition to native apoA-I, we investigated the effects of the cardioprotective Milano variant (Arg173Cys).

• Författare: Karin Stenkula; Maria Lindahl; Jitka Petrlova; Jonathan Dalla-Riva; Olga Göransson; Sam Cushman; Ewa Krupinska; Helena Jones; Jens Lagerstedt
• Avdelning/ar: EXODIAB: Excellence of Diabetes Research in Sweden; Medical Protein Science; Institutionen för experimentell medicinsk vetenskap; Translationell Muskel Forskning; Molekylär endokrinologi
• Publiceringsår: 2014
• Språk: Engelska
• Sidor: 797-800
• Publikation/Tidskrift/Serie: Diabetologia
• Volym: 57
• Issue: 4
• Länkar: http://www.ncbi.nlm.nih.gov/pubmed/24442447?dopt=Abstract; http://dx.doi.org/10.1007/s00125-014-3162-7
• Dokumenttyp: Artikel i tidskrift
• Förlag: Springer
• Ämne: Endocrinology and Diabetes
• Status: Published
• Forskningsgrupp: Medical Protein Science; Genomics, Diabetes and Endocrinology; Molecular Endocrinology
• ISBN/ISSN/Övrigt: ISSN: 1432-0428